Currently, the typical regimen for patients undergoing transplant surgery is either minoxidil and/or finasteride -- or possibly dutasteride. A word of caution with all current drug-based options is the potential for negative side effects. Alternatively, in the past decade a series of hair loss treatments have been developed containing natural compounds and phytochemicals. These generally offer an excellent safety profile, however, with rare exception, they remain largely unsupported by peer-reviewed data. Recognizing that inflammation contributes to a wide range of diseases, including those affecting the skin and hair, it is our view that the blockade of inflammation in susceptible hair follicles represents a new and potentially viable therapeutic avenue. The enhanced outcome potential for using anti-inflammatory compounds with 5-AR inhibitors is amenable for testing in the setting of transplant surgery.